TrialBMC neurology2021

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial.

David Kudrow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.